LYZZ Capital logo

LYZZ Capital

Asia, Shanghai, China, Shanghai

Description

LYZZ Capital is a venture capital firm specialized in seed, early, and expansion stage venture investments.

Investor Profile

LYZZ Capital has made 8 investments, with 0 in the past 12 months and 13% as lead.

Stage Focus

  • Series B (63%)
  • Series A (25%)
  • Series D (13%)

Country Focus

  • United States (100%)

Industry Focus

  • Biotechnology
  • Health Care
  • Medical
  • Pharmaceutical
  • Therapeutics
  • Health Diagnostics
  • Wellness
  • Biopharma
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does LYZZ Capital frequently co-invest with?

Madison Partners
North America, California, United States, Los Angeles
Co-Investments: 2
HBM Healthcare Investments
Europe, Zug, Switzerland, Zug
Co-Investments: 2
Private Ventures Group ("PVG")
North America, New York, United States, New York
Co-Investments: 1
Boehringer Ingelheim Venture Fund
Europe, Rheinland-Pfalz, Germany, Ingelheim Am Rhein
Co-Investments: 2
City Hill Ventures
North America, California, United States, San Diego
Co-Investments: 2
Delos Capital
North America, New York, United States, New York
Co-Investments: 2
Lumira Ventures
North America, Ontario, Canada, Toronto
Co-Investments: 2
Korea Investment Partners
Asia, Seoul-t'ukpyolsi, South Korea, Seoul
Co-Investments: 2
Xeraya Capital
Asia, Kuala Lumpur, Malaysia, Kuala Lumpur
Co-Investments: 2
B Capital
North America, California, United States, Manhattan Beach
Co-Investments: 2

What are some of recent deals done by LYZZ Capital?

OncoMyx Therapeutics

Phoenix, Arizona, United States

OncoMyx Therapeutics develops oncolytic immunotherapies to assist in creating an immune response and treat cancer.

BiotechnologyHealth DiagnosticsMedicalTherapeutics
Series BDec 9, 2021
Amount Raised: $50,000,000
Viron

Boston, Massachusetts, United States

Viron Inc. is based in Boston, MA

Health Care
Series BDec 8, 2021
Amount Raised: $50,000,000
Wugen

St Louis, Missouri, United States

Wugen is developing off-the-shelf cellular therapies targeting solid tumors and hematologic malignancies

BiotechnologyTherapeutics
Series BJul 15, 2021
Amount Raised: $172,000,000
Neurelis

Encinitas, California, United States

Neurelis is a specialty pharmaceutical company providing a highly differentiated approach to target unmet medical needs.

BiotechnologyHealth CareMedicalPharmaceutical
Series DMar 10, 2021
Amount Raised: $114,000,000
Jumpcode Genomics

Carlsbad, California, United States

JUMPCODE's CRISPR-mediated rRNA depletion kits remove nucleic acids from sequencing workflows to improve sensitivity and performance.

BiotechnologyHealth CareWellness
Series BJan 20, 2021
Amount Raised: $21,000,000
Onchilles Pharma

San Diego, California, United States

Onchilles Pharma is a biotechnology company developing first-in-class biologics therapies for the treatment of cancer.

BiopharmaBiotechnologyPharmaceutical
Series AJul 10, 2020
Amount Raised: $7,000,000
Qpex Biopharma

San Diego, California, United States

Qpex Biopharma develops a pipeline of agents addressing critical needs for the treatment of infectious diseases.

BiotechnologyHealth Care
Series AOct 22, 2018
Amount Raised: $33,000,000
Neurelis

Encinitas, California, United States

Neurelis is a specialty pharmaceutical company providing a highly differentiated approach to target unmet medical needs.

BiotechnologyHealth CareMedicalPharmaceutical
Series BJan 5, 2017
Amount Raised: $42,098,000